Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen Pfizer Inc. and Merck & Co. Inc. announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with Merck’s investigational anti-PD-1 antibody pembrolizumab, in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with anaplastic lymphoma kinase-positive advanced or metastatic non-small cell lung cancer. [Merck & Co., Inc.] Press Release Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer Advaxis, Inc. has entered into a clinical trial collaboration agreement with Merck to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s investigational anti PD-1 antibody, pembrolizumab. [Advaxis, Inc.] Press Release OncoMed Pharmaceuticals Announces Removal of Partial Clinical Hold by the FDA for Vantictumab OncoMed Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on enrollment in the company’s vantictumab (anti-Fzd7, OMP-18R5) Phase I clinical trials. Vantictumab is being studied in combination with standard-of-care chemotherapy in three Phase Ib clinical trials in patients with advanced non-small cell lung cancer, advanced HER2-negative breast cancer and advanced pancreatic cancer. [OncoMed Pharmaceuticals, Inc.] Press Release Herbert Irving Comprehensive Cancer Center Has Designation Renewed by National Cancer Institute; Awarded $18 Million Grant Outstanding basic research, a growing focus on translating discoveries into treatments, and a dedication to patient care have earned the Herbert Irving Comprehensive Cancer Center of Columbia University Medical Center and New York-Presbyterian Hospital an $18 million, five-year Cancer Center Support Grant from the National Cancer Institute. [Columbia University Medical Center] Press Release Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) Sorrento Therapeutics, Inc. announced that it has received funding to advance an immunotherapy targeting WNT1-inducible signaling protein-1 for the potential treatment of IPF, which affects more than 100,000 Americans. [Sorrento Therapeutics, Inc.] Press Release TxCell Granted Five New Patents in Major Global Territories for Core Technology and ASTrIA Platform since January 2014 TxCell SA, a biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells for chronic inflammatory and autoimmune diseases, announced that five new patents for their technologies have been issued in the Unites States, Asia and Australia since the beginning of 2014. [TxCell SA] Press Release Cellular Dynamics Awarded U.S. Patent Covering Automated Production of All Human Pluripotent Stem Cells Cellular Dynamics International announced that the U.S. Patent and Trademark Office (PTO) awarded the company Patent No. 8,815,585 on the automated production of human pluripotent stem cells, including induced pluripotent stem cells. This patent has broad-reaching effects, covering research, cellular therapy development and stem cell banking. [Cellular Dynamics International, Inc.] Press Release Glenmark Enters Oncology with the Discovery and the Initiation of IND Enabling Studies of an Innovative Bispecific Antibody Glenmark Pharmaceuticals S.A. announced the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. [Glenmark Pharmaceuticals S.A.] Press Release AFL Approves Use of Regeneus’ Stem Cell Therapy, HiQCell for Injured Players Regeneus Ltd. announced that the Australian Football League (AFL) has granted case-by-case approval for the use of its innovative stem cell therapy, HiQCell® as a treatment option for injured AFL players, typically including impact related osteoarthritis and tendonitis. [Regeneus Ltd.] Press Release |